4 results about "Apoptosis resistance" patented technology

The present invention relates to the stratification and treatment of patients suffering of cancer. Due to the fact that anti-PD1 therapy targets lymphocytes and the efficiency of anti-cancer therapy is measured by the impact on the tumor cells, the inventors postulated that studying the molecular mechanisms of resistance of anti-PD1 therapy should take into consideration existing intercellular communication between lymphocytes and tumor cells. As exosomes are the carriers for the intercellular transfer of the miRNA responsible of chemoresistance, they herein investigated whether exposure of T cells to anti-PD1 therapy might promote the expression of exosomal miRNA (exomiR) causing the chemoresistance of cancer cells. Surprisingly, they found that anti-PD1 exposure of T-cell promotes an enrichment of exosomal miRNA-4315. They also noted that exosomal miRNA-4315 induced a phenomenon of apopto-resistance to conventional chemotherapies in cancer cells receiving exosomal miRNA-4315. At molecular level, they discern that the apopto-resistance phenomenon was associated with the miRNA-4315-mediated down-regulation of Bim, a pro-apoptotic protein. In cellular and mice models, they observed that the BH3 mimetic agent ABT263 circumvented this resistance. Thus, the invention relates to methods of stratification using exosomal miRNA-4315 and method of treatment of patients suffering of cancer using BH3 mimetic agent.

The present application relates to 5-[1,2,4-oxadiazole]-6-oxygen-pyrazolopyridine derivatives and preparation method and application thereof, and the 5-[1,2,4-oxadiazole]-6-oxygen-pyrazolopyridine derivatives and pharmaceutically acceptable salts thereof, the general formula is as shown in formula (II): wherein, the definition of substituent group is described in the specification. The 5-[1,2,4-oxadiazole]-6-oxygen-pyrazolopyridine derivatives and pharmaceutically acceptable salts thereof of the present application have the functions of inhibiting Hsp110-STAT3 interaction, thereby down-regulating p-STAT3 and c-Myc levels, inhibiting pulmonary arterial endothelial cell proliferation, migration and apoptosis resistance, reducing pulmonary arterial pressure and improving the degree of pulmonary vascular remodeling, and further playing the role of anti-pulmonary arterial hypertension.

The invention relates to the technical field of biological medicines, in particular to an AAV virus vector carrying a VEGFB (vascular endothelial growth factor B) gene and application of the AAV virus vector in preparation of a medicine for treating retinitis pigmentosa. The invention provides an AAV virus vector carrying a VEGFB gene and application of the vector in preparation of a medicine for treating retinitis pigmentosa. A VEGFB gene is combined with an AAV virus vector to construct a recombinant virus vector capable of effectively transfecting retinal cells and expressing VEGFB protein, and effective treatment on retinitis pigmentosa is realized by utilizing biological functions of oxidation resistance, apoptosis resistance, angiogenesis inhibition and the like of the VEGFB protein.

The invention relates to the technical field of biological medicines and nano preparations, in particular to a preparation method and application of a ginseng-sourced nano-like particle loaded medicine. The method comprises the following steps: S1, extracting a ginseng exosome; s2, purifying the ginseng exosome; and S3, preparing the drug-loaded nanoparticles. According to the invention, GENs is taken as an oral carrier, the problem of low bioavailability of free drugs is solved, the drug stability is enhanced by a natural phospholipid double-layer structure, and intestinal absorption and liver targeting accumulation are facilitated. The dual effects of the active ingredient of the GENs and the loaded drug are obviously better than that of a single drug; and oxidation resistance, inflammation resistance, fibrosis resistance and apoptosis resistance are synchronously realized. By repairing ZO-1 / Occludin, an intestinal barrier is reconstructed, intestinal toxin entering the liver is reduced, and meanwhile, liver injury and fibrosis disappearance are improved; a new strategy is provided for high-valued transformation of ginseng resources, and the safety of the plant exosome is far higher than that of a synthetic vector.